UK Fines Advanz Pharma $140 Million for Inflating Thyroid Tablet Prices

August 2, 2021

The UK’s Competition and Markets Authority (CMA) has fined UK-based drugmaker Advanz Pharma and two private equity firms nearly $140 million for allegedly charging inflated prices for a drug used to treat thyroid hormone deficiency.

The CMA said Advanz supplied liothyronine tablets at “excessive and unfair prices,” with the price of thyroid tablet packs increasing from less than $28 in 2009 to nearly $345 in 2017, an increase of 1,110 percent.

The dramatic price hike led to a huge increase in costs for the National Health Service and “meant that people dealing with depression and extreme fatigue, as a result of their thyroid conditions, were told they could not continue to receive the most effective treatment for them due its increased price,” said CMA’s CEO Andrea Coscelli.

View today's stories